Despite the decrease in tumor growth observed with BMX-IN-1 as a single agent, we reasoned that the MES-to-NOR phenotypic transition induced by BMX inhibition may constitute an opportunity for synergistic therapeutic combinations, given that the resistance of NB tumors toward conventional chemotherapy is often attributed to their enrichment in MES cells. This evidence concerns the gene BMX and neuroblastoma.